David A. Siegel Rhythm Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 8,900 shares of RYTM stock, worth $435,477. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,900Holding current value
$435,477% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding RYTM
# of Institutions
178Shares Held
69.1MCall Options Held
467KPut Options Held
224K-
Primecap Management CO Pasadena, CA7.31MShares$358 Million0.22% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$330 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$313 Million3.49% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$298 Million3.77% of portfolio
-
Goldman Sachs Group Inc New York, NY5.29MShares$259 Million0.04% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $2.73B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...